RegiSCAR Score for DRESS
Validates a suspected case of drug reaction with eosinophilia and systemic symptoms (DRESS) with the RegiSCAR scoring system (Kardaun 2007): total −4 to 9; < 2 no case, 2–3 possible, 4–5 probable, > 5 definite.
Score interpretation
Score below 2: not a DRESS case by RegiSCAR.
→ DRESS unlikely; consider alternative diagnosis; monitor drug reaction; review causative agent
RegiSCAR 2–3: possible DRESS.
→ Stop causative drug; specialist dermatology review; monitor FBC, LFTs, renal function, CXR; avoid re-exposure; consider systemic steroids if progressing
RegiSCAR 4–5: probable DRESS.
→ Emergency admission; stop causative drug immediately; systemic corticosteroids (Adults: prednisolone 1mg/kg/day. Children: use a children's formulary.); ophthalmology (eye involvement); dermatology, hepatology, nephrology involvement; ICU if multiorgan failure
RegiSCAR above 5: definite DRESS.
→ Emergency admission; stop causative drug immediately; systemic corticosteroids (Adults: prednisolone 1mg/kg/day. Children: use a children's formulary.); ophthalmology (eye involvement); dermatology, hepatology, nephrology involvement; ICU if multiorgan failure
Interpretation bands for the RegiSCAR (DRESS). Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Thalidomide (Rheumatology / Dermatology) · Immunomodulatory Drug (IMiD)
- Phenylephrine · Alpha-1 Adrenergic Agonist (Pure Vasoconstrictor)
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Omalizumab (Dermatology — Chronic Urticaria) · Anti-IgE Monoclonal Antibody
- Apremilast (Dermatology) · Phosphodiesterase-4 (PDE4) Inhibitor
- Carbimazole · Antithyroid Drug
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.